ISB 2001, a BCMA and CD38 Dual Targeting T Cell Engager, Demonstrates Superior Cytotoxicity Relative to Teclistamab in the Samples of Patient Relapsing from CD38 and BCMA Targeted Immunotherapies
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined